Reproxalap for Dry Eye Faces Repeated Regulatory Rejections

The experimental drug reproxalap demonstrated significant symptom reduction in patients with dry eye disease during a recent clinical trial, yet the U.S. Food and Drug Administration has declined to approve it for this indication on multiple occasions.

Reproxalap, a small-molecule inhibitor targeting reactive aldehyde species, was evaluated in a Phase 2b study for its ability to alleviate signs and symptoms of dry eye syndrome, also known as keratoconjunctivitis sicca. Results showed statistically significant improvements in ocular discomfort, visual disturbances and tear film stability compared to placebo, according to data presented at a major ophthalmology conference and reported by Medscape Medical News.

Despite these positive outcomes, the FDA has issued complete response letters in prior review cycles, citing insufficient evidence of clinical meaningfulness and concerns over the durability of treatment effect. Agency reviewers have questioned whether the observed symptom improvements translate into meaningful benefits for patients’ daily functioning or long-term ocular health.

Dry eye disease affects an estimated 16 million adults in the United States and is characterized by inadequate lubrication of the ocular surface, leading to inflammation, discomfort, and potential damage to the cornea. It is increasingly recognized as a multifactorial condition involving tear film instability, ocular surface inflammation, and neurosensory abnormalities. Current treatments include artificial tears, anti-inflammatory agents like cyclosporine and lifitegrast, and procedural interventions such as punctal plugs.

Reproxalap’s mechanism of action differs from existing therapies by targeting oxidative stress pathways implicated in ocular surface damage. Specifically, it inhibits aldehyde-generated modifications of proteins and lipids that contribute to inflammation and cellular dysfunction in the lacrimal functional unit. Preclinical models have shown that reproxalap reduces markers of oxidative stress and inflammation in corneal and conjunctival tissues.

The drug is being developed by Aldeyra Therapeutics, which has also investigated reproxalap for other inflammatory conditions, including noninfectious uveitis and allergic conjunctivitis. While early-phase data in uveitis showed promise, the company has shifted focus toward dry eye as a primary indication due to the high unmet need and large patient population.

Regulatory hesitation underscores the FDA’s evolving standards for approval in dry eye disease, where demonstration of symptom relief alone may not suffice without corroborating evidence of functional improvement or objective biomarkers of ocular surface health. The agency has emphasized the importance of patient-reported outcomes that reflect real-world impact, such as difficulty with reading, screen use, or night driving.

Aldeyra Therapeutics has not disclosed plans for a resubmission or additional trials to address the FDA’s concerns. Analysts note that securing approval may require new data demonstrating sustained benefit over longer treatment periods or superiority to existing therapies in head-to-head comparisons.

As of now, reproxalap remains an investigational drug, and patients with dry eye disease should continue to rely on FDA-approved treatments under the guidance of an eye care professional. Further clinical investigation will be necessary to determine whether reproxalap can meet the regulatory threshold for approval in this challenging therapeutic area.